ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Memory in Parkinson's Disease (ProMem)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00913640
Recruitment Status : Completed
First Posted : June 4, 2009
Last Update Posted : July 16, 2009
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by:
Washington University School of Medicine

Brief Summary:
The investigators tested whether prospective memory is impaired in individuals with Parkinson's Disease compared to controls using reliable and validated experimental measures. Also, the investigators assessed the impact of Parkinson's medication on prospective memory performance in PD to better estimate prospective memory function in PD patients' everyday (chronically treated) life.

Condition or disease
Memory Prospective Memory Parkinson's Disease

Study Type : Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Prospective Memory in Parkinson's Disease

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
PD Group
Control Group



Primary Outcome Measures :
  1. Prospective Memory


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Community Movement Disorder Clinic at Washington University St. Louis
Criteria

Inclusion Criteria:

  • PD Group:

    • Clinically definite PD
    • 40-70 years old
    • Hoehn and Yahr stage I,II,III
    • Currently treated with Levodopa/carbidopa
  • Control Group:

    • 40-70 years old
    • Spouses of PD Group preferred

Exclusion Criteria:

  • PD Group and Control Group:

    • Significant neurological problems
    • Significant current psychiatric diagnoses
    • Mini Mental Status Exam score < 24 (MMSE)
    • Any significant abnormality on brain imaging
    • MPTP exposure
    • Control Participants met the same exclusion criteria described above as well as a biological family history of PD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913640


Locations
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
National Institutes of Health (NIH)
Investigators
Principal Investigator: Tamara G Hershey, Ph.D. Washington University School of Medicine

Additional Information:
Responsible Party: Tamara G Hershey PhD.,, Washington University
ClinicalTrials.gov Identifier: NCT00913640     History of Changes
Other Study ID Numbers: 05-0203
First Posted: June 4, 2009    Key Record Dates
Last Update Posted: July 16, 2009
Last Verified: July 2009

Keywords provided by Washington University School of Medicine:
Prospective Memory Performance
Prospective Memory Outcome
Parkinson's Disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases